https://www.selleckchem.com/pr....oducts/brm-brg1-atp-
Sample size estimation determined that ~225 randomized subjects would be required to evaluate noninferiority for this primary clinical efficacy endpoint, and superiority for a renal function safety endpoint. Our findings provide the basis for future delayed CNI substitution noninferiority trials, thereby increasing the likelihood they will provide clinically implementable results and achieve regulatory approval.Increased use of azithromycin (AZ) in treating infections associated with coronavirus disease 2019 (COVID-19)
Like
Comment
Share
